Muramyl dipeptide

Muramyl dipeptide (MDP) is a synthetic immunoreactive peptide, consisting of N-acetyl muramic acid attached to a short amino acid chain of L-Ala-D-isoGln. Muramyl dipeptide is an inducer of bone formation through induction of Runx2. Muramyl dipeptide directly enhances osteoblast differentiation by up-regulating Runx2 gene expression through MAPK pathways. Muramyl dipeptide is a NLRP1 agonist[1][2].

Product Specifications

CAS Number

[53678-77-6]

Product Name Alternative

MDP

UNSPSC

12352211

Hazard Statement

H315, H319

Target

NOD-like Receptor (NLR) ; p38 MAPK

Type

Reference compound

Related Pathways

Immunology/Inflammation; MAPK/ERK Pathway

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/muramyl-dipeptide.html

Concentration

10mM

Purity

98.0

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : 50 mg/mL (ultrasonic)

Smiles

CC(N[C@@H](C=O)[C@H]([C@H](O)[C@H](O)CO)O[C@H](C)C(N[C@@H](C)C(N[C@@H](C(N)=O)CCC(O)=O)=O)=O)=O

Molecular Formula

C19H32N4O11

Molecular Weight

492.48

Precautions

H315, H319

References & Citations

[1]Park OJ, et al. Muramyl Dipeptide, a Shared Structural Motif of Peptidoglycans, Is a Novel Inducer of Bone Formation through Induction of Runx2. J Bone Miner Res. 2017 Jul;32 (7) :1455-1468.|[2]V Kaushal, et al. Neuronal NLRP1 inflammasome activation of Caspase-1 coordinately regulates inflammatory interleukin-1-beta production and axonal degeneration-associated Caspase-6 activation. Cell Death Differ. 2015 Oct;22 (10) :1676-86.